Ph3b Adjuvant Ribociclib HR+HER2 Breast Cancer (Adjuvant Wider)
Phase III Clinical Trial
A phase IIIb study to characterize the efficacy and safety of ADJUVANT ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (ADJUVANT WIDER) (CLEE011O12001)